Global Brain Tumor Diagnosis and Treatment Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2031

Brain Tumor Diagnosis and Treatment Market Analysis

The brain tumor diagnosis and treatment market is experiencing substantial growth driven by advancements in biotechnology and molecular research. Developments in this field includes the introduction of innovative cell lysis technologies that offer higher efficiency and better preservation of cellular components. Companies are now focusing on developing more refined and automated systems that integrate seamlessly into various research workflows. For instance, the introduction of microfluidic devices and acoustic lysis systems has revolutionized how researchers handle and process cell samples, providing precise control over the lysis process and minimizing sample loss. Additionally, advancements in reagent formulations and the development of novel consumables are enhancing the versatility and effectiveness of brain tumor diagnosis and treatment techniques. The market is also benefiting from increased investments in research and development by pharmaceutical and biotechnology companies, as well as a growing emphasis on personalized medicine and regenerative therapies.

Brain Tumor Diagnosis and Treatment Market Size

The global brain tumor diagnosis and treatment market size was valued at USD 618.28  million in 2023 and is projected to reach USD 1,129.23 million by 2031, with a CAGR of  7.82% during the forecast period of 2024 to 2031. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Brain Tumor Diagnosis and Treatment Market Trends

“Rising Adoption of Enzymatic Cell Dissociation Methods”

O mercado de diagnóstico e tratamento de tumores cerebrais está a crescer devido aos avanços nas tecnologias de imagem e na medicina personalizada. Uma tendência chave no mercado é a crescente adoção de técnicas de biópsia líquida para diagnóstico precoce e não invasivo. As biópsias líquidas, que analisam o ADN tumoral circulante (ctDNA) na corrente sanguínea, oferecem uma alternativa menos invasiva às biópsias de tecidos tradicionais. Por exemplo, empresas como a Biocept desenvolveram plataformas de biópsia líquida que detectam biomarcadores de tumores cerebrais, permitindo um diagnóstico mais precoce e um melhor planeamento do tratamento. Esta tecnologia é especialmente benéfica para monitorizar a progressão do tumor e a resposta ao tratamento em tempo real. Além disso, os avanços nas terapias dirigidas, como a imunoterapia e a radiação de precisão, estão a proporcionar opções de tratamento mais eficazes e com menos efeitos secundários. Estas inovações, combinadas com a crescente incidência de tumores cerebrais e a procura de ferramentas de diagnóstico minimamente invasivas, estão a impulsionar o crescimento do mercado de diagnóstico e tratamento de tumores cerebrais, melhorando os resultados dos doentes e aumentando o potencial do mercado.

Âmbito do relatório e segmentação do mercado de diagnóstico e tratamento de tumores cerebrais

Definição de mercado de diagnóstico e tratamento de tumor cerebral

O diagnóstico e tratamento de tumores cerebrais referem-se aos processos médicos utilizados para identificar e gerir crescimentos anormais de células no cérebro. O diagnóstico envolve normalmente tecnologias de imagem como a ressonância magnética (ressonância magnética) e a tomografia computorizada (tomografia computorizada) para detetar tumores, juntamente com técnicas como a biópsia, onde é examinada uma amostra do tumor. Métodos emergentes, como biópsias líquidas e diagnóstico molecular, também estão a ser utilizados para deteção não invasiva. O tratamento abrange várias abordagens dependendo do tipo, localização e estádio do tumor, incluindo cirurgia, radioterapia, quimioterapia, terapia dirigida e imunoterapia. O objetivo é remover ou diminuir o tumor, minimizando os danos no tecido cerebral saudável e preservando a função neurológica.

Dinâmica do mercado de diagnóstico e tratamento de tumores cerebrais

Motoristas

• Aumento da incidência de tumores cerebrais

A crescente incidência de tumores cerebrais impulsiona significativamente o mercado de diagnóstico e tratamento de tumores cerebrais. De acordo com o relatório Global Cancer Burden and Strategies for Cancer Control (GLOBOCAN) 2020, ocorreram 19,3 milhões de novos casos de cancro a nível mundial em 2020, com quase 10,0 milhões de mortes atribuídas ao cancro. A crescente prevalência é influenciada por fatores como as exposições ambientais à radiação e aos poluentes químicos, juntamente com as predisposições genéticas. À medida que os casos de tumores cerebrais continuam a aumentar, aumenta a procura de ferramentas de diagnóstico avançadas, como a imagiologia de alta resolução e o diagnóstico molecular, juntamente com uma necessidade crescente de opções de tratamento inovadoras, incluindo terapias específicas e imunoterapias. O aumento da incidência alimenta diretamente a necessidade de desenvolvimento contínuo e adoção de soluções de ponta, impulsionando o crescimento do mercado de diagnóstico e tratamento de tumores cerebrais.

• Programas crescentes de sensibilização e rastreio

Os crescentes programas de sensibilização e rastreio estão a ter um impacto significativo na deteção e diagnóstico precoces de tumores cerebrais, levando a um aumento da procura de soluções de diagnóstico e terapêutica. As iniciativas de saúde pública e as campanhas educativas estão a desempenhar um papel crucial nesta mudança. Por exemplo, organizações como a American Brain Tumor Association (ABTA) realizam campanhas de sensibilização que educam o público sobre os sintomas do tumor cerebral e a importância do rastreio precoce. Tais esforços têm sido associados a uma maior participação em programas de rastreio, como os exames de RM para indivíduos com maior risco ou que apresentam sintomas. A campanha “Mês de Sensibilização para os Tumores Cerebrais”, que aumenta a consciencialização sobre os sinais de tumores cerebrais e incentiva a consulta médica atempada, está a divulgar ainda mais os programas de sensibilização e rastreio. À medida que mais pessoas tomam consciência da importância da deteção precoce e procuram serviços de rastreio, aumenta a procura por ferramentas de diagnóstico avançadas e opções de tratamento eficazes, impulsionando ainda mais o crescimento do mercado de diagnóstico e tratamento de tumores cerebrais.

Oportunidades

• Avanços nas tecnologias de imagem

Os avanços nas tecnologias de imagem estão a aumentar significativamente a precisão e a eficácia do diagnóstico de tumores cerebrais. Por exemplo, o desenvolvimento de técnicas avançadas de ressonância magnética, como a ressonância magnética de alto campo e a ressonância magnética funcional (fMRI), oferece informações detalhadas sobre a atividade cerebral e a morfologia do tumor, melhorando a localização e caracterização do tumor. Além disso, as tecnologias de imagem molecular, incluindo a tomografia por emissão de positrões (PET) com marcadores radiomarcados, fornecem informações valiosas sobre a atividade metabólica e a proliferação das células tumorais, o que é crucial para avaliar o comportamento do tumor e a resposta ao tratamento. Especificamente, os exames PET com 18F-FDG demonstraram a capacidade de diferenciar com precisão os tipos de tumor e avaliar a eficácia do tratamento em doentes com tumor cerebral. Estas inovações não só melhoram a precisão do diagnóstico, como também criam oportunidades para as empresas desenvolverem e comercializarem soluções de imagiologia de ponta, atendendo à crescente procura de ferramentas de diagnóstico avançadas no mercado dos tumores cerebrais.

• Expansão das terapias dirigidas e imunoterapias

The expansion of targeted therapies and immunotherapies is transforming the treatment landscape for brain tumors, providing new avenues for combating these challenging conditions. Targeted therapies focus on specific genetic mutations that drive tumor growth, offering a more tailored approach to treatment. For instance, temozolomide is a chemotherapy drug designed to target the DNA repair mechanisms unique to certain brain tumors, such as glioblastomas. Immunotherapies, such as CAR-T cell therapy, where T cells are engineered to recognize and attack tumor cells, showing potential in treating brain tumors such as glioblastoma by targeting cancer cells while minimizing damage to healthy tissue. Companies that invest in these advanced treatment options can capitalize on these innovations, meeting the rising demand for effective brain tumor therapies and improving patient outcomes. Consequently creating great opportunities in the market growth.

Restraints/Challenges

• Complexity of Brain Tumors

The complexity of brain tumors presents a significant challenge in both diagnosis and treatment, as these tumors exhibit considerable variability in their types, locations, and genetic profiles. For instance, glioblastomas, a highly aggressive type of brain tumor, differ markedly from meningiomas, which generally have a better prognosis and less aggressive behavior. Glioblastomas often have diverse genetic mutations and varying responses to treatment, necessitating highly specialized diagnostic tools such as advanced MRI imaging and genetic profiling to accurately identify and understand the tumor's characteristics. Similarly, treatment plans must be tailored to each tumor's specific genetic and molecular features, requiring a multidisciplinary approach involving neurosurgeons, oncologists, and radiologists. This complexity not only complicates the development of standardized treatment protocols but also makes it challenging to implement personalized therapies consistently. Consequently hampering the brain tumor diagnosis and treatment market.

• Limited Availability of Advanced Diagnostic and Treatment Technologies

The limited availability of advanced diagnostic and treatment technologies significantly impacts the quality of care in the brain tumor market, creating disparities between well-equipped centers and those with fewer resources. For instance, cutting-edge imaging systems such as high-field MRI scanners and PET-CT systems, which are crucial for accurate tumor localization and monitoring, are often found only in specialized centers or high-income countries. Patients in lower-income regions or less developed healthcare settings may not have access to these technologies, leading to delays in accurate diagnosis and suboptimal treatment planning. Such disparity is exemplified by the availability of novel therapeutic agents, such as targeted therapies or immunotherapies, which may only be accessible through clinical trials or in countries with advanced healthcare infrastructure.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Brain Tumor Diagnosis And Treatment Market Scope

The market is segmented on the basis of product type, product analysis, diagnosis type, treatment type, and end-user. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product Type

• Primary Brain Tumor
  • Meningioma
  • Gliomas
  • Astrocytomas
  • Pituitary Tumors
  • Others
• Secondary Brain Tumor

Product Analysis

• Stains and Varnishes
• Shellacs
• Lacquers
• Others

Diagnosis Type

• CT Scan
• MRI
• PET-CT Scan
• Molecular Testing
• EEG
• Others

Treatment Type

• Surgery
• Radiation Therapy
• Targeted Therapy
• Chemotherapy
• Immunotherapy

End User

• Hospitals
• Ambulatory Surgical Centers

Brain Tumor Diagnosis And Treatment Market Regional Analysis

The market is analysed and market size insights and trends are provided by country, product type, product analysis, diagnosis type, treatment type, and end-user as referenced above.

The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America leads the brain tumor diagnosis and treatment market, primarily due to significant research and development efforts, a high incidence of brain tumor diagnoses, and increasing awareness of treatment and management options. The region's advanced healthcare infrastructure, coupled with substantial investments in oncology research, further strengthens its dominance in this market. Additionally, growing public awareness about early diagnosis and available treatment methods contributes to the rising demand for advanced brain tumor therapies in North America.

Europe is projected to witness the highest growth rate in the brain tumor diagnosis and treatment market during the forecast period of 2024 to 2031. This growth is largely driven by government initiatives aimed at raising awareness of advanced medical technologies and improving access to cutting-edge treatments across the region. Additionally, increased investment in healthcare infrastructure and research, along with growing public awareness about early diagnosis and advanced therapies, is expected to fuel the market's expansion in Europe.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.  

Brain Tumor Diagnosis and Treatment Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Brain Tumor Diagnosis and Treatment Market Leaders Operating in the Market Are:

• Pfizer Inc. (U.S.)
• Mayo Foundation for Medical Education and Research (MFMER) (U.S.)
• GE HealthCare (U.S.)
• AstraZeneca (U.K.)
• Merck & Co., Inc. (U.S.)
• Siemens Healthineers AG (Germany)
• Carestream Health (U.S.)
• Hitachi, Ltd. (Japan)
• Koninklijke Philips N.V. (Netherlands)
• Shimadzu Corporation (Japan)
• Canon Medical Systems (Japan)
• Eisai Co., Ltd. (Japan)
• Elekta (Sweden)
• Varian Medical Systems, Inc. (U.S.)
• FUJIFILM Corporation (Japan)
• NantOmics (U.S.)
• Hologic, Inc. (U.S.)
• Thermo Fisher Scientific Inc. (U.S.)
• Genentech, Inc. (U.S.)
• Bristol-Myers Squibb Company (U.S.)

Latest Developments in Brain Tumor Diagnosis And Treatment Market

• In March 2024, AstraZeneca completed the acquisition of Fusion Pharmaceuticals, aiming to accelerate advancements in cancer treatment. This acquisition is focused on shifting away from conventional therapies like chemotherapy and radiotherapy, towards more innovative and targeted approaches that enhance patient outcomes
• In January 2024, GE HealthCare acquired MIM Software, a company specializing in AI-driven imaging and workflow solutions. This acquisition enables GE HealthCare to integrate MIM’s advanced AI-enabled tools into sectors such as oncology and neurology, enhancing diagnostic accuracy and improving treatment planning across these critical healthcare domains

SKU-60266